Table 7.

Recommendations on duration of dual antiplatelet therapy following percutaneous coronary intervention in acute coronary syndrome

Indications	Grade of recommendation	Level of evidence
In patients with ACS undergoing PCI, regardless of stent type, dual antiplatelet therapy should be maintained for a minimum period of 12 months	I	A
In patients with ACS undergoing PCI with increased risks of bleeding, it is possible to consider maintaining dual antiplatelet therapy for a minimum period of 6 months	IIa	B
In patients with ACS undergoing PCI with a drug-eluting stent who tolerate the routine dual antiplatelet therapy duration without bleeding episodes and who have low bleeding risks and high atherothrombotic risks (DAPT score ≥ 2 and PRECISE-DAPT < 25), it is possible to maintain antiplatelet therapy for > 12 months and ≤ 30 months	IIb	A

ACS: acute coronary syndrome; PCI: percutaneous coronary intervention.